Joint (JYNT) Stock Price, News & Analysis

Company Overview

Joint, Inc. (NASDAQ: JYNT) operates a digital imaging and telemedicine platform tailored for the veterinary industry, providing on-demand diagnostic services to enhance patient care and clinical efficiency. The company’s core offerings include digital radiography, ultrasound, MRI and CT imaging, combined with cloud-based tele-interpretation services. By integrating with leading practice management systems, Joint streamlines scheduling, image acquisition and reporting, allowing veterinary practices to access board-certified radiologists and immediate diagnostic insights without the overhead of in-house imaging suites.

In addition to its teleradiology network, Joint deploys mobile imaging units staffed by trained technologists, enabling clinics across urban and rural markets to offer advanced diagnostics on-site. The company’s proprietary software delivers secure image transfer, automated quality checks and structured reporting, reducing turnaround times and improving case throughput. Joint also provides consulting services to help practices optimize equipment selection, workflow design and compliance protocols, positioning itself as an end-to-end partner for veterinary diagnostic expansion.

Founded in the late 2010s by a multidisciplinary team of veterinarians, software engineers and medical imaging experts, Joint has scaled its footprint throughout North America. It serves a broad spectrum of clinics—from single-doctor practices to regional referral centers—in all 50 states and parts of Canada. The company’s growth has been driven by strategic alliances with equipment manufacturers and practice management vendors, as well as targeted investments in network infrastructure and data analytics to support predictive care and population health management.

Joint’s executive leadership combines deep experience in veterinary medicine, digital health innovation and medical imaging. The management team focuses on product development, regulatory compliance and strategic partnerships to drive both organic growth and market expansion. As the veterinary sector continues to embrace telehealth and advanced diagnostics, Joint aims to extend its platform with AI-driven image analysis, expanded service lines and broader geographic coverage to meet evolving clinician and patient needs.

Key Stats

• Today's Range: $11.75 to $12.27
• 50-Day Range: $9.81 to $12.51
• 52-Week Range: $9.58 to $15.32
• Volume: 48,042 shs
• Average Volume: 55,000 shs
• Market Capitalization: $183.45 million
• P/E Ratio: 1,175.00
• Dividend Yield: N/A
• Price Target: $15.50
• Consensus Rating: Buy

Joint Stock Analysis - MarketRank™

Joint scored higher than 60% of companies evaluated by MarketBeat, and ranked 400th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Joint has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Joint has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 381.82%

Earnings Growth

Earnings for Joint are expected to grow by 381.82% in the coming year, from $0.11 to $0.53 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Joint is -20.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Joint is -20.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Joint has a P/B Ratio of 9.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.84% of the float of Joint has been sold short.

Short Interest Ratio / Days to Cover

Joint has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Joint has recently increased by 0.96%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Joint does not currently pay a dividend.

Dividend Growth

Joint does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.84% of the float of Joint has been sold short.

Short Interest Ratio / Days to Cover

Joint has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in Joint has recently increased by 0.96%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Joint this week, compared to 2 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Joint insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.90% of the stock of Joint is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.88% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JYNT Stock Analysis - Frequently Asked Questions

How have JYNT shares performed this year?

Joint's stock was trading at $10.63 at the start of the year. Since then, JYNT stock has increased by 12.8% and is now trading at $11.99.

How were Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. The business had revenue of $13.08 million for the quarter, compared to analyst estimates of $13.02 million. Joint had a negative net margin of 9.86% and a positive trailing twelve-month return on equity of 1.60%.
Read the conference call transcript.

Is Joint buying back stock?

Joint's Board of Directors approved a stock buyback program on Thursday, June 5th 2025, which permits the company to repurchase $5,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 2.7% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's management believes its stock is undervalued.

When did Joint IPO?

Joint (JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.

How do I buy shares of Joint?

Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Joint own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Joint investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - HMO
• Sub-Industry: Trading
• Current Symbol: NASDAQ:JYNT
• CIK: 1612630
• Web: www.thejoint.com
• Phone: (480) 245-5960
• Fax: 480-513-7989
• Employees: 320
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.50
• High Stock Price Target: $16.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +31.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 106.82
• P/E Growth: N/A
• Net Income: -$8.53 million
• Net Margins: -9.86%
• Pretax Margin: -1.79%
• Return on Equity: 1.60%
• Return on Assets: 0.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.59
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $51.90 million
• Price / Sales: 3.46
• Cash Flow: $0.66 per share
• Price / Cash Flow: 17.89
• Book Value: $1.20 per share
• Price / Book: 9.79

Miscellaneous

• Outstanding Shares: 15,300,000
• Free Float: 11,033,000
• Market Cap: $179.78 million
• Optionable: Optionable
• Beta: 1.49